During the last session, Nektar Therapeutics (NASDAQ:NKTR)’s traded shares were 1.85 million, with the beta value of the company hitting 0.63. At the end of the trading day, the stock’s price was $0.76, reflecting an intraday loss of -5.46% or -$0.04. The 52-week high for the NKTR share is $1.93, that puts it down -153.95 from that peak though still a striking 14.47% gain since the share price plummeted to a 52-week low of $0.65. The company’s market capitalization is $141.03M, and the average intraday trading volume over the past 10 days was 1.58 million shares, and the average trade volume was 2.02 million shares over the past three months.
Nektar Therapeutics (NKTR) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.11. NKTR has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.18.
Nektar Therapeutics (NASDAQ:NKTR) trade information
Nektar Therapeutics (NKTR) registered a -5.46% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -5.46% in intraday trading to $0.76, hitting a weekly high. The stock’s 5-day price performance is -13.23%, and it has moved by -2.86% in 30 days. Based on these gigs, the overall price performance for the year is -14.67%. The short interest in Nektar Therapeutics (NASDAQ:NKTR) is 6.95 million shares and it means that shorts have 3.38 day(s) to cover.
The consensus price target of analysts on Wall Street is $18.5, which implies an increase of 95.89% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $24 respectively. As a result, NKTR is trading at a discount of -3057.89% off the target high and -689.47% off the low.
Nektar Therapeutics (NKTR) estimates and forecasts
In the rating firms’ projections, revenue will decrease -36.41% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 15.61M as predicted by 9 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to 15.7M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 21.64M and 23.49M respectively. In this case, analysts expect current quarter sales to shrink by -27.88% and then drop by -33.15% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 25.49%. While earnings are projected to return -8.45% in 2025, the next five years will return -11.68% per annum.
NKTR Dividends
Nektar Therapeutics is due to release its next quarterly earnings on 2025-Mar-11. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Nektar Therapeutics (NASDAQ:NKTR)’s Major holders
Nektar Therapeutics insiders own 1.26% of total outstanding shares while institutional holders control 71.87%, with the float percentage being 72.79%. DEEP TRACK CAPITAL, LP is the largest shareholder of the company, while 180.0 institutions own stock in it. As of 2024-06-30, the company held over 17.88 million shares (or 8.5599% of all shares), a total value of $22.17 million in shares.
The next largest institutional holding, with 15.16 million shares, is of BLACKROCK INC.’s that is approximately 7.2575% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $18.79 million.
Also, the Mutual Funds coming in first place with the largest holdings of Nektar Therapeutics (NKTR) shares are MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . Data provided on Dec 31, 2024 indicates that MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund owns about 6.65 shares. This amounts to just over 3.57 percent of the company’s overall shares, with a $5.04 million market value. The same data shows that the other fund manager holds slightly less at 5.72, or about 3.08% of the stock, which is worth about $4.34 million.
